Erythropoietin (Epo) is used in clinical settings to enhance hematopoietic function and to improve the quality of life for patients undergoing chemotherapy by reducing fatigue and the need for transfusions. However, several meta-analyses have revealed that Epo treatments are associated with an increased risk of mortality in cancer patients. In this study, we examined the role of Epo in prostate cancer (PCa) progression, using in vitro cell culture systems and in vivo bone metastatic assays. We found that Epo did not stimulate the proliferation of PCa cell lines, but did protect PCa cells from apoptosis. In animal models of PCa metastasis, no evidence was found to support the hypothesis that Epo enhances metastasis. Together, these findings suggest that Epo may be useful for treating severe anemia in PCa patients without increasing metastatic risk.
the primary growth factor known to regulate the production of erythrocytes [Dempke et al., 2000] . Although Epo improves quality of life (QoL) in anemic patients, there remains considerable controversy over the use of Epo for cancer patients as an alternative to blood transfusion.
In adults, the major source of Epo is the kidney, from which it travels through the blood stream to the bone marrow to control red blood cell production. In addition to its enhancement of red blood cell production, Epo has recently been demonstrated to have protective effects on non-erythropoietic tissues (e.g., neuroprotection and cardioprotection) through its receptor (EpoR) [Arcasoy, 2008] . This suggests that Epo not only improves hematopoietic conditions, but also provides other health benefits. Yet several meta-analyses have revealed an association between Epo treatment and increased mortality in cancer patients [Dicato and Plawny, 2010; Hedley et al., 2011] . Moreover, it has been demonstrated that various cancer cells express EpoR [Acs et al., 2001; Arcasoy et al., 2003 Arcasoy et al., , 2005 Jeong et al., 2008] , and that Epo may promote tumor progression by stimulating tumor growth [Acs et al., 2001 ], or angiogenesis [Ribatti, 2010] . To date, however, little is known regarding the mechanisms whereby Epo may stimulate tumor progression, the roles of EpoR in tumor progression, and the relationship between Epo and metastasis.
Recently, we reported that high dose Epo enhances bone formation by directly stimulating HSC production of BMPs, and by activating bone formation by mesenchymal stem cells [Shiozawa et al., 2010] . We also recently demonstrated that prostate cancer (PCa) cells that disseminate to the bone marrow compete directly with HSCs for occupancy of the HSC niche [Shiozawa et al., 2011] . We therefore hypothesized that one mechanism whereby Epo could increase mortality in cancer patients is by expanding the number of HSC niches, and therefore increasing the opportunity for metastasis. In this study we found that Epo did not stimulate the growth of PCa cells in vitro, nor did Epo enhance PCa bone metastasis in vivo. However, we did observe that Epo protected PCa cell lines from apoptosis. Although our findings reveal that Epo may not directly support PCa tumor growth and metastasis to bone, there remains a significant need to further understand the biological effects of Epo treatment in cancer.
MATERIALS AND METHODS

CELL CULTURE
The human PCa cell line PC3 and normal human prostate epithelial cell line RWPE1 were obtained from the American Type Culture Collection (Rockville, MD). The human metastatic subline LNCaP C4-2B was originally isolated from a lymph node of a patient with disseminated bony and lymph node involvement [Wu et al., 1998 ]. PCa cell lines were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) with 10% (v/v) fetal bovine serum (FBS; Invitrogen), and 1% (v/v) penicillin-streptomycin (Invitrogen), and maintained at 37°C, 5% CO 2 , and 100% humidity.
RNA EXTRACTION AND REAL-TIME RT-PCR
Total RNA was isolated using RNeasy Mini Kit (QIAGEN, Valencia, CA). First-strand cDNA was synthesized in a 20 ml reaction volume using 0.4 mg of total RNA. RT products were analyzed by real-time PCR in TaqMan® Gene Expression Assays for human EpoR and bactin (Applied Biosystems, Foster City, CA). Reactions without template and/or enzyme were used as negative controls. The PCR reactions were run for 50 cycles (95°C for 15 s and 60°C for 1 min) after an initial single cycle of 50°C for 2 min and 95°C for 10 min. The PCR product was detected as an increase in fluorescence using an ABI PRISM 7,700 instrument (Applied Biosystems). RNA quantity (C R ) was normalized to the housekeeping gene b-actin by using the formula C R ¼ 2ð40 À C t of sampleÞ À ð40 À C t of controlÞ. The threshold cycle (C t ) is the cycle at which a significant increase in fluorescence occurs.
FLOW CYTOMETRY
PCa cell lines and RWPE1 cells were stained with APC anti-human monoclonal EpoR antibody (R&D systems, Minneapolis, MN). The levels of EpoR were analyzed by a FACSAria dual laser flow cytometer (Becton Dickinson, Franklin Lakes, NJ). In some cases, PCa cells and RWPE1 cells (80-90% confluent) were cultured in 6-well plates in RPMI medium without FBS for 5 h. After serum starvation, the cells were treated with 20 U/ml of Epo (EPOGEN; Amgen, Thousand oaks, CA) for 30 min. The phosphorylation of p44/42 MAP kinase (Thr202/ Tyr204), or Erk1/2, and Akt were analyzed with flow cytometry, using total Erk1/2 and Akt as internal controls. Antibodies for phosphorylated Erk1/2, phosphorylated Akt, total Erk1/2, and total Akt were purchased from Cell Signaling Technology.
WESTERN BLOT ANALYSES
PCa cells and RWPE1 cells were extracted for protein and analyzed for EpoR (R&D systems) by Western blot analysis. b-actin (Cell Signaling Technology) was used as an internal control for loading.
SDS-PAGE was performed in 10% polyacrylamide gels. After electrophoresis, the proteins were transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules, CA). The membranes were then incubated with the primary antibody overnight, followed by horseradish peroxidase conjugated secondary antibody (Cell Signaling Technology, Danvers, MA). Proteins were visualized by autoradiography using an enhanced chemiluminescence detection system (Amersham Pharmacia, Piscataway, NJ). 
PROLIFERATION ASSAYS
IN VIVO METASTASIS ASSAYS
Luciferase-expressing PC3 (PC3 Luc ) cells were introduced into male SCID mice by intracardiac injections. For 4 weeks prior to or post tumor inoculation, the recipient mice were treated by intraperitoneal injections with Epo (6,000 U/kg/day, three times per week) or vehicle. Bone metastatic regions were measured by bioluminescence imaging. Total tumor burden of each animal was calculated using regions of interest (ROI) that encompassed the entire animal.
COL2.3D-TK ANIMALS AND TREATMENTS
Transgenic mice bearing a fusion gene composed of the 2.3-kb fragment of the rat type I collagen a1 (Col1a1) promoter and HSV-TK (Col2.3D-TK) [Visnjic et al., 2001] were graciously provided by Dr. David W. Rowe (University of Connecticut, Farmington, CT). Four-to 6-week-old mice bearing the Col2.3DTK transgene and age-matched control CD-1 mice were intraperitoneally injected with ganciclovir (Cytovene-IV; Roche, Nutley, NJ; 3-8 mg/kg per day), or vehicle (0.9% saline) for 3 weeks with/without PTH (hPTH 1À34 ; Bachem, Torrence, CA; 50-80 mg/kg per day), or Epo (6,000 U/kg/day, three times per week) injections.
BONE MARROW TRANSPLANTATION ASSAYS
Prior to bone marrow transplantation, mice were treated with PTH or Epo to expand the bone marrow niche. Recipient mice were exposed twice to 570 cGy given 3 h apart in a gamma cell 40 cesium source. One hour later the mice were injected intravenously with a mixture of a radioprotective dose of CD45.2 cells (2 Â 10 5 cells) and CD45.1 donor cells in 100 ml. Starting at 4 weeks after transplantation and continuing for at least 16 weeks, the CD45.1 phenotypes were measured in peripheral blood. (Fig. 1A) . To further evaluate if EpoR mRNA expression is correlated with protein levels, cell surface EpoR expression was analyzed by flow cytometry using commercially available anti-EpoR antibodies. Although the expression of EpoR is extremely low in all cell types, the level of expression of EpoR protein by PCa cells was detected and was higher than that seen in RWPE1 cells (Fig. 1B) . These observations were further confirmed by Western blotting (Fig. 1C) .
STATISTICAL ANALYSES
To determine if EpoR expressed on PCa cells is activated in response to Epo treatment, phosphorylation of Erk1/2 and Akt in treated PCa and RWPE1 cells were evaluated by flow cytometry. The data demonstrated that Epo induces phosphorylation of Erk1/2 in both PC3 and C4-2B cells, while it had no effect on RWPE1 cells ( Fig.  2A) . A similar trend was observed in the phosphorylation of Akt (Fig.  2B ). These data suggest that activation of PCa cells by Epo through EpoR is possible.
To determine whether Epo regulates proliferation of PCa cells through EpoR, in vitro XTT assays were performed. After 2 days of culture with and without varying concentrations of Epo, we observed no effect on proliferation of the PCa cells (Fig. 2C,D) .
EPO PROTECTS PCA CELLS FROM APOPTOSIS
To determine if Epo can regulate PCa survival, apoptosis initiated by serum starvation in the presence or absence of Epo was evaluated by flow cytometry using annexin V staining methods. The data demonstrate that significantly fewer apoptotic cells were detected in Epo-treated cells than controls (Fig. 3A) .
The maintenance and protection from apoptosis and injury of HSCs in the marrow is predominantly a function of the HSC endosteal niche, a region largely populated by osteoblasts [Shiozawa and Taichman, 2012] . Recently, we demonstrated that PCa cells target this region in marrow to establish metastatic footholds, and that the niche protects PCa cells from apoptosis [Shiozawa et al., 2011] . To address whether the protective role of Epo is dependent on the osteoblastic niche, we used a genetically engineered animal model, in which thymidine kinase is placed under control of the collagen I promoter (hereinafter referred to as Col2.3D-TK animals). In this animal model ganciclovir treatment conditionally ablates osteoblasts in the marrow [Visnjic et al., 2004] . In this experiment, parathyroid hormone (PTH) was used as a control, since it has also been shown to expand osteoblastic niches [Calvi et al., 2003 ]. Without ganciclovir, there were no differences in the number of hematopoietic cells in the marrow between vehicle, PTH, and Epo treatment in this animal model (Fig. 3B) . In contrast, the number of osteoblasts in PTH and Epo treated animals were increased (Fig. 3C ). Ganciclovir alone had no effect on the number of hematopoietic cells in the marrow of control animals ( Fig. 3B) , but dramatically decreased the number of osteoblasts in Col2.3D-TK animals regardless of treatment (Fig. 3C) . Interestingly, Epo treatment prevented the cells from undergoing apoptosis initiated by the ablation of osteoblastic niche, whereas neither vehicle nor PTH treatment protected the marrow cells from apoptosis (Fig. 3B) . Therefore, although this experiment was performed in the hematopoietic system, the data suggest that Epo protects cells from apoptosis, but in a niche-independent manner.
EPO DOES NOT DIRECTLY REGULATE BONE METASTASIS OF PCA CELLS
To explore if Epo is critical for the development of bone metastases in vivo, luciferase-expressing PC3 cells (PC3 Luc cells) were inoculated into SCID mice by intracardiac injection. The animals were treated either with vehicle, Epo prior to tumor inoculation, or Epo post tumor inoculation. Development of bone metastases was followed over time using bioluminescence imaging. Surprisingly, neither pre-treatment with Epo nor treatment after tumor inoculation altered the development of bone metastases (Fig. 4A) . Recently, we demonstrated that pre-treatment of animals with anabolic dosing of PTH increased bone metastasis from PCa cells by expanding the bone marrow niche size [Shiozawa et al., 2011] . Based upon the fact that the Epo has a protective effect on the cells in the marrow (Fig. 3B) , we hypothesized that the occupancy of the marrow space by the cells protected by Epo would prevent the cell trafficking process to the marrow, even if Epo also expands the size of niche. To test this hypothesis, two sets of studies were performed. First, bone marrow transplantation assays with/without Epo treatment were performed, since the homing process of HSCs well represents the cell 
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trafficking process to the marrow. As a control for the niche expansion, mice were also treated with PTH. There were no significant differences between treatments when analyzing % engraftment of transfused cells to the marrow of recipient mice (Fig. 4B ). As before, although this experiment was performed in the hematopoietic system, the data suggest that the cell trafficking to the marrow may not be directly correlated to niche numbers. At the molecular level, it has been well accepted that SDF-1 secreted by the bone marrow microenvironment plays an important role in bone metastasis, including PCa [Muller et al., 2001; Taichman et al., 2002] . Therefore, we hypothesized that SDF-1 expression in marrow is responsible for the differences in the metastatic potential between PTH-and Epo-treated mice, and thus SDF-1 levels in the marrow were evaluated by immunohistochemistry. As expected, PTH-treated mice express more SDF-1 in the marrow, compared to vehicle-treated mice (Fig. 4C) . Surprisingly, lower levels of SDF-1 expression were observed in the bone marrow of Epo-treated mice, compared to PTH-treatments (Fig. 4C ).
DISCUSSION
In this study, we examined the role of Epo in PCa tumor progression using in vitro cell culture models and in vivo metastatic assays. We found that Epo does not enhance the proliferation of PCa cell lines in vitro, however, it does prevent cells from undergoing apoptosis when stressed by serum starvation. More importantly, we observed that Epo does not affect the metastatic cascade of PCa cells in an in vivo model of metastasis. Together, our data suggest that promotion of PCa metastasis or induction of proliferation by PCa cells are unlikely to be the cause of enhanced mortality following Epo therapy in PCa.
While the biological roles of Epo in erythropoiesis and tissue protection has been revealed [Arcasoy, 2008] , the use of Epo for treatment of anemia in cancer patients is still controversial. Recent clinical studies have suggested that Epo adversely affects the prognosis in cancer patients. It has been suggested that Epo promotes tumor growth through EpoR, and that Epo activates several signaling pathways (Jak2/Stat3, PI3K/AKT, MAPK) [Hedley et al., 2011] . Indeed, some in vitro studies have demonstrated that Epo enhances tumor proliferation [Westenfelder and Baranowski, 2000; Acs et al., 2001; Yasuda et al., 2003; Feldman et al., 2006] . However, others have demonstrated that no effects of Epo on tumor growth were observed in vitro [Dunlop et al., 2006; Jeong et al., 2008] , and in vivo [Kataoka et al., 2010] . Our current study failed to reveal any stimulatory effects of Epo on tumor growth, however, we did find that Epo inhibits PCa cell apoptosis. As most assays to determine cell proliferation measure the number of viable cells, data obtained from these assays do not always correlate with cell proliferation. Therefore, an alternative explanation for the differences seen in various studies may be in the nature of the assays themselves. Consistent with these findings, it has been demonstrated that Epo protects tumor cells from cytotoxic insults through EpoR [Brines et al., 2004; Arcasoy, 2008] . Previous in vitro studies may have interpreted the cell protective role of Epo as cell proliferation rather than a decrease in apoptosis. Epo is believed to activate a signal transduction cascade in cancer cells through its receptor on their surface. However, the roles of Epo in non-hematopoietic tissues, including cancer cells, remain conflicting. EpoR mRNA expression has been detected in several tumors and cancer cell lines [Acs et al., 2001; Arcasoy et al., 2003; Arcasoy et al., 2005; Jeong et al., 2008] . Although EpoR protein was detected by flow cytometry and Western blotting in this study, there remains debate as to whether commercially available antibodies for EpoR are adequately specific and EpoR, a membrane receptor, is often detected in cytoplasm [Jelkmann and Laugsch, 2007] . Moreover, Epo may bind to diverse receptors to activate cancer cells, since EpoR exist as a multi-receptor complex with a b common receptor [Jubinsky et al., 1997; Brines et al., 2004] . As a result, the direct interaction between Epo and EpoR in cancer cells is not yet fully understood. Conversely, Epo may affect tumor progression indirectly by stimulating angiogenesis [Ribatti, 2010] . For example, studies have demonstrated that anti-angiogenic therapy reduces tumor sizes [Ingber et al., 1990; O 0 Reilly et al., 1994 O 0 Reilly et al., , 1997 Folkman, 1995] , suggesting that vasculature surrounding tumor cells supports tumor growth. It has also been reported that Epo enhances angiogenesis by mobilizing endothelial progenitor cells (EPCs) from bone marrow [Heeschen et al., 2003; Bahlmann et al., 2004] . However, the contribution of either Epo itself or to EPC-induced tumor vascularization has not yet been observed in an in vivo setting [Jelkmann and Elliott, 2012] . In addition to these observations, endothelial cells in other non-hematopoietic tissue may also express Epo mRNA and functional EpoR, yet these results remain contentious [Sinclair et al., 2010] . Collectively, while the subject of Epo production outside of the kidney and EpoR expression remains in debate, the effects of Epo on tumor progression may be substantially limited. Clearly, further studies are needed. Epo has been thought to improve QoL in the patients undergoing chemotherapy by reducing fatigue and the need for blood transfusions. Recent clinical trials testing the prophylactic effects of Epo on chemotherapy-induced anemia were terminated early, since Epo increased mortality in cancer patients [Leyland-Jones, 2003; Wright et al., 2007] . It was initially speculated this is due mainly to tumor growth initiated by Epo. However, growing evidence suggests that Epo may initiate thrombosis, resulting in a higher mortality [Fandrey and Dicato, 2009] , although detailed mechanisms are still unknown. One potential means behind this may be due to hyperviscosity caused by increased red blood cell production and reduction of plasma volume [Spivak et al., 2009] . Epo is also believed to enhance platelet levels by stimulating the production or release of other inflammatory cytokines [Spivak et al., 2009] . Often in cancer patients, hypercoagulation and enhanced platelet aggregation are observed. Importantly, recent studies suggest that platelets play a crucial role in tumor progression and metastasis [Gay and Felding-Habermann, 2011] . Platelets are believed to promote the migration/invasion of tumor cells, maintain their survival in the blood stream, protect them from immunosurveillance, and support the establishment of metastases in secondary sites [Gay and Felding-Habermann, 2011] . Nevertheless, many of these postulated events in tumor progression were not mimicked in our model of bone metastasis. Therefore, a direct effect of Epo on tumor progression may be possible, or Epo may influence the metastatic cascade in different ways than were examined in our study.
Little is known regarding the impact of Epo on the metastatic process, although this drug may have profound effects on local tumor progression. It has been demonstrated that primary solid tumors spread to the marrow utilizing similar mechanisms as HSC homing [Muller et al., 2001; Taichman et al., 2002] . We have recently demonstrated that disseminated PCa cells travel to the HSC niche and then take up the residence in the niche to eventually form a metastasis [Shiozawa et al., 2011] . These findings suggest that the HSC niche plays an essential role in the development of metastasis. As seen with PTH (12), we recently reported that Epo expands the HSC niche in the marrow by either directly driving the differentiation of mesenchymal stem cells or indirectly through BMP signaling by HSCs [Shiozawa et al., 2010 ]. In our current study, Epo did not increase bone metastasis of PCa, despite a resultant increase in the niche with treatment in this transgenic animal model. A potential reason for this discrepancy may be the SDF-1 response in the bone marrow to Epo and PTH. SDF-1 is a ligand for the chemokine receptors CXCR4 and CXCR7 [Sun et al., 2010] . The one of major roles of SDF-1 is to serve as a chemoattractant for CXCR4/7 expressing tumor cells and HSCs [Sun et al., 2010] . We found that PTH treatment stimulates the secretion of SDF-1 in the marrow, however, we observed here that when animals were treated with Epo, SDF-1 levels in the marrow were suppressed. These data suggest that Epo affects the HSC niche differently from PTH, and as a result these two hormones may have opposite effects on bone metastasis, even though they both expand the niche size.
Excluding venous thrombosis, adverse effects of Epo treatment for cancer patients are still largely controversial. Despite concerns about the mortality risk, Epo is, however, still a viable treatment option for cancer patients with anemia, as it could potentially improve their QoL and reduce the need for transfusions. Therefore, further welldesigned, controlled clinical trials in this area are clearly warranted in order to ensure the safe use of Epo for treatment of anemia in cancer patients. Ultimately, whether prophylactic Epo treatment is appropriate should be decided on a case-by-case basis until the existence of functional EpoR, the impacts of EpoR on the prognosis, and the roles of Epo/EpoR in tumor progression are biologically determined.
